Blood protein levels predict leading incident diseases and mortality in UK Biobank

Danni A. Gadd(Edinburgh Cancer Research), Robert F. Hillary(Edinburgh Cancer Research), Zhana Kuncheva(Optimat (United Kingdom)), Tasos Mangelis(Optimat (United Kingdom)), Yipeng Cheng, Manju Dissanayake, Romi Admanit(Biogen (United States)), Jake Gagnon(Biogen (United States)), Tin-Chi Lin(Biogen (United States)), Kyle Ferber(Biogen (United States)), Heiko Runz(Biogen (United States)), Biogen Biobank Team(Edinburgh Cancer Research), Riccardo E. Marioni(Edinburgh Cancer Research), Christopher N. Foley(Biogen (United States)), Benjamin B. Sun(Biogen (United States))
medRxiv
May 3, 2023
Cited by 32Open Access
Full Text

Abstract

Abstract The circulating proteome offers insights into the biological pathways that underlie disease. Here, we test relationships between 1,468 Olink protein levels and the incidence of 23 age-related diseases and mortality, over 16 years of electronic health linkage in the UK Biobank (N=47,600). We report 3,201 associations between 961 protein levels and 21 incident outcomes, identifying proteomic indicators of multiple morbidities. Next, protein-based scores (ProteinScores) are developed using penalised Cox regression. When applied to test sets, six ProteinScores improve Area Under the Curve (AUC) estimates for the 10-year onset of incident outcomes beyond age, sex and a comprehensive set of 24 lifestyle factors, clinically-relevant biomarkers and physical measures. Furthermore, the ProteinScore for type 2 diabetes outperformed a polygenic risk score, a metabolomic score and HbA1c – a clinical marker used to monitor and diagnose type 2 diabetes. These data characterise early proteomic contributions to major age-related disease and demonstrate the value of the plasma proteome for risk stratification.


Related Papers

No related papers found

Powered by citation graph analysis